Sunday, June 3, 2018
10:00 AM - 5:00 PM
Room 208, Level 2
Boston Convention Center
The Product & Company Valuation course is designed to teach a systematic approach to producing a valuation which can be used in investment rounds, mergers/acquisitions, licensing deals or strategic development decisions in the pharma-biotech world. It goes beyond the number-crunching techniques of most consultants and includes difficult to define qualitative factors which shape the risk profile of the company in question.
Valuation is an inherently subjective task which is made even more difficult in the life science industry due its unique challenges: high attrition rates in R&D, long investment cycle, complex technologies and IP situations, etc. Therefore, traditional valuation methods are not suitable. Of particular value in this course is the Product Valuation and Deal Structuring module where you will learn the commonly used rNPV (risk-adjusted Net Present Value) method for calculating the value of a drug in development. Subsequently, you will practice how to structure a licensing deal between companies. You will use an Excel-based tool designed specifically for this module (which can be taken home).
Sunday, June 3, 2018
|10:00 AM - 10:15 AM||Welcome|
|10:15 AM - 11:00 AM||Introduction to Valuation: What – Why - When|
|11:00 AM - 11:30 AM||How to Assess a Company Prior to Valuation|
|11:30 AM - 11:45 AM||Break|
|11:45 AM - 1:30 PM||Company Valuation|
|1:30 PM - 2:15 PM||Lunch|
|2:15 PM - 4:45 PM||Product Valuation & Deal Structuring|
|4:45 PM - 5:00 PM||Final Discussion & Wrap-up|
2018 Product and Valuation Course Instructor:
Patrik Frei, CEO & Founder, Venture Valuation
Patrik Frei is a leading expert in the valuation of life science companies and his combination of knowledge and experience allows him to speak with authority on the subject. Patrik wrote the first book on the valuation of high-growth companies and holds a Ph.D in the field. His company, Venture Valuation, has completed over 400 independent company and product valuations.
- Introduction to Valuation
- Assessing a Company Prior to Valuation
- Company Valuation and Methods
- Product Valuation and Methods
- Deal Structuring
Who should attend?
This is an introductory course and therefore very valuable for pharma and biotech executives who are not familiar with compound and company valuations but need a thorough understanding of the valuation concepts and techniques that are commonly applied in the pharma and biotech industries.
*Content is subject to modification.